A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "

A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer " - JACCRO CC-16AR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034885

Enrollment

Registered

2018-11-15

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were registered in the JACCRO CC-16 trial (jRCTs061180002), include the following: (1) Approved to supply the tissue sample for this study by IRB. (2) Written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who were regarded as inadequate for study enrollment by investigators. (2) Patients who refused to supply the tumor samples.

Design outcomes

Primary

Measure	Time frame
Association between protein in plasma at pre-treatment and progression-free survival	—

Secondary

Measure	Time frame
- Association between protein in plasma at post-treatment and progression-free survival - Association between protein in plasma at pre-treatment and response rate or overall survival - Association between protein in plasma at post-treatment and response rate or overall survival - Association between novel biomarkers and clinical outcomes	—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Research Organization (JACCRO) Research Office

cc16ar.dc@jaccro.or.jp03-6811-0433

Outcome results